MULTIPLE MYELOMA
MORE THAN ONE PLASMA CELL TUMOR
PLASMACYTOMA
SINGLE PLASMA CELL TUMOR
ISOLATED PLASMACYTOMA
myeloma cells also interfere with cells that help keep the bones strong myeloma cells make a substance that tells the osteoclasts to speed up dissolving the bone fractured bones are a major problem in people with myeloma
abnormal plasma cells do not protect the body from infections the antibody made by myeloma cells can harm the kidneys. This can lead to kidney damage and even kidney failure. Median survival time for patients with multiple myeloma is 3 to 5 years. Death usually results from infection.
AGE
FAMILY HX
GENDER
WORKPLACE EXPOSURES
RACE
OBESITY
RADIATION
RISK FACTORS
CLINICAL MANIFESTATIONS
Pain intensity increases during day Excessive thirst Dehydration Constipation Confusion
Manifested by
ANEMIA
Epistaxis Headache Blurred vision Paresthesia
HYPERVISCOSITY
Manifested by
X-RAY
CBC
CONFIRMATORY
Medical Management
Primary tx
Chemotherapy
-Strengthening the bone at a specific lesion -Relieving bone pain -Reducing tumor size
Radiation Therapy
Vertebroplasty
Biophosphonates
Medical Management
hyperviscosity Plasmapheresis
Thalidomide
Antimyeloma effects
-Inhibits cytokines -Boosting bodys immune response -Creating favorable conditions for apoptosis of the myeloma cells
CC-5013
ACTIVITY RESTRICTIONS
HEALTH EDUCATION ON HYPERCALCEMIA
3 L/day